BioCentury
ARTICLE | Clinical News

Dermagraft: Development discontinued

August 29, 2011 7:00 AM UTC

Shire said it will discontinue development of Dermagraft to treat venous leg ulcers after top-line data from the open-label, international Phase III DEVO trial in >500 patients showed that weekly Dermagraft combined with Profore compression therapy missed the primary endpoint of complete healing defined as 100% re-epithelialization with no presence of scab or drainage of ulcers by week 16 vs. compression therapy alone. Details were not disclosed. ...